卓然股份(688121.SH):控股子公司向其全資子公司增資
格隆匯6月19日丨卓然股份(688121.SH)公佈,爲充分利用公司資源,進一步提高內部運營及管理效率,公司控股子公司卓科擬將其相關資產注入至其全資子公司卓和,以資產注入形式進行增資。本次注入涉及的資產包括但不限於房屋、構築物、機器設備、在建工程、土地使用權等固定資產及無形資產,注入資產在2025年5月31日的評估價值約爲69,637.26萬元,劃轉資產將用於認繳註冊資本。上述資產的最終劃轉金額以劃轉實施結果爲準。本次增資完成後,卓和仍爲卓科的全資子公司;本次資產注入系公司內部資產注入事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.